- Nassal M, Schaller H. Hepatitis B virus replication‐an update. Journal of viral hepatitis. 1996;3(5):217-26.
2. Rabe B, Vlachou A, Panté N, Helenius A, Kann M. Nuclear import of hepatitis B virus capsids and release of
the viral genome. Proceedings of the National Academy of Sciences. 2003;100(17):9849-54.
3. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000;64(1):51-68.
4. Carman WF, Karayiannis P, Waters J, Thomas H, Zanetti A, Manzillo G, et al. Vaccine-induced escape mutant
of hepatitis B virus. The lancet. 1990;336(8711):325-9.
5. Avellon A, Echevarria JM. Frequency of hepatitis B virus ‘a’determinant variants in unselected Spanish
chronic carriers. Journal of medical virology. 2006;78(1):24-36.
6. Kramvis A, Kew M, Francois G. Hepatitis B virus genotypes. Vaccine. 2005;23(19):2409-23.
7. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. Journal of
Gastrointestinal and Liver Diseases. 2007;16(4):403.
8. Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH, et al. Clearance of hepatitis
B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology. 2007;133(5):1452-
7.
9. Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. Hepatitis B Virus infection in
Iran: A systematic review. Hepatitis monthly. 2008;8(4).
10. Arababadi MK, Pourfathollah AA, Jafarzadeh A, Hassanshahi G, Rezvani ME. Association of exon 9 but not
intron 8 VDR polymorphisms with occult HBV infection in south‐eastern Iranian patients. Journal of gastroenterology
and hepatology. 2010;25(1):90-3.
11. Poorolajal J, Majdzadeh R. Prevalence of chronic hepatitis B infection in Iran: a review article. Journal of
research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2009;14(4):249.
12. Flink HJ, Van Zonneveld M, Hansen BE, De Man RA, Schalm SW, Janssen HL. Treatment with Peginterferon α-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. The American
journal of gastroenterology. 2006;101(2):297.
13. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention
and control measures. Journal of viral hepatitis. 2004;11(2):97-107.
14. Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology. 2009;49(S5):S112-
S21.
15. Nishijima N, Marusawa H, Ueda Y, Takahashi K, Nasu A, Osaki Y, et al. Dynamics of hepatitis B virus
quasispecies in association with nucleos (t) ide analogue treatment determined by ultra-deep sequencing. PloS one.
2012;7(4):e35052.
16. Yeh C-T. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside
analogue therapy. Antiviral therapy. 2010;15(3):471.
17. Locarnini SA, Yuen L. Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir Ther.
2010;15(3 Pt B):451-61.
18. Hammitt LL HT, Fiore AE, Zanis C, Hummel KB, Dunaway E, Bulkow L, McMahon BJ. . Hepatitis B
immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years.
Vaccine. 2007;25:6958-64.
19. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in
hepatitis B virus infection. Journal of hepatology. 2009;51(3):581-92.
20. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus
infection. Proceedings of the National Academy of Sciences. 1996;93(9):4398-402.
21. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos (t) ide analogues. Gastroenterology.
2009;137(5):1593-608. e2.
22. Yamamoto K HM, Tsuda F, Itoh K, Akahane Y, Yotsumoto S, Okamoto H, Miyakawa Y, Mayumi M. .
Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for
antibody to hepatitis B surface antigen. Journal of virology. 1994;68:2671-6.
23. Chen CH, Hung CH, Lee CM, Hu TH, Wang JH, Wang JC, et al. Pre-S deletion and complex mutations of
hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology. 2007;133(5):1466-74.
24. W G. Diagnostic problems caused by HBsAg mutants—a consensus report of an expert meeting. Intervirology.
2004;47:310-3.
25. Block TM, Guo H, Guo J-T. Molecular virology of hepatitis B virus for clinicians. Clinics in liver disease.
2007;11(4):685-706.
- 26. Cento V, Mirabelli C, Dimonte S, Salpini R, Han Y, Trimoulet P, et al. Overlapping structure of hepatitis B
virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution. Journal of General
Virology. 2013;94(1):143-9.
27. Pollicino T, Isgrò G, Di Stefano R, Ferraro D, Maimone S, Brancatelli S, et al. Variability of reverse
transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic
hepatitis B patients. Antivir Ther. 2009;14(5):649-54.
28. Garrido E, Gariglio P, Jindadamrongwech S, Smith DR, Carrillo E, Coursaget P, et al. Diagnostic problems
caused by HBsAg mutants–a consensus report of an expert meeting. Intervirology. 2004;47(6):310-3.
29. Mahinrousta S, Sharafi H, Alavian S, Behnava B, Pouryasin A. Study of HBsAg escape mutations in chronic
hepatitis B patients under treatment with nucleos (t) ide analogues. 2012.
30. Sayan M, Şentürk Ö, Akhan S, Hülagü S, Cekmen M. Monitoring of hepatitis B virus surface antigen escape
mutations and concomitantly nucleos (t) ide analog resistance mutations in Turkish patients with chronic hepatitis B.
International Journal of Infectious Diseases. 2010;14:e136-e41.
31. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. Journal of
clinical virology. 2005;34:S1-S3.
32. Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. Journal of antimicrobial
chemotherapy. 2008;61(4):766-8.
33. Salpini R, Colagrossi L, Bellocchi MC, Surdo M, Becker C, Alteri C, et al. Hepatitis B surface antigen genetic
elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. Hepatology.
2015;61(3):823-33.
34. Pan CQ, Duan ZP, Bhamidimarri KR, Zou HB, Liang XF, Li J, et al. An algorithm for risk assessment and
intervention of mother to child transmission of hepatitis B virus. Clinical gastroenterology and hepatology.
2012;10(5):452-9.
35. Oon CJ, Chen WN, Goo KS, Goh KT. Intra-familial evidence of horizontal transmission of hepatitis B virus
surface antigen mutant G145R. Journal of Infection. 2000;41(3):260-4.
36. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase
genes of hepatitis B virus. Journal of clinical virology. 2002;25(2):97-106.
37. Hsieh Y-H, Su I-J, Wang H-C, Chang W-W, Lei H-Y, Lai M-D, et al. Pre-S mutant surface antigens in chronic
hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis. 2004;25(10):2023-32.
38. Salpini R, Svicher V, Cento V, Gori C, Bertoli A, Scopelliti F, et al. Characterization of drug-resistance
mutations in HBV D-genotype chronically infected patients, naive to antiviral drugs. Antiviral research.
2011;92(2):382-5.
|
